ArticleVeterinary research2026
A recombinant adenoviral vector vaccine expressing the ORF2 capsid protein confers robust protection against chicken astrovirus infection.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chicken astrovirus (CAstV), which causes enteritis, nephritis, and growth retardation syndrome, including white chicken syndrome (WCS), represents a significant global economic burden, with no available vaccine. Its fecal-oral transmission route underscores the need for mucosal immunity at intestinal entry sites, while human adenovirus type 5 (HAdV-5) vectors are highly efficient at targeting mucosal tissues. To develop and evaluate a novel recombinant adenovirus-vectored vaccine against CAstV, we used the HAdV-5 vector (AdMax system) to construct rAd5-CAstV-ORF2, which expresses the immunodominant CAstV ORF2 capsid protein. The ORF2 gene was seamlessly cloned into the shuttle plasmid (pcADV-EF1-mNeonGreen-CMV) and packaged into human embryonic kidney (HEK293T) cells. The rAd5-CAstV-ORF2 vaccine achieved a high titer (6.32 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.